ReviewFrontiers in bioengineering and biotechnology2025
Iron oxide nanoparticles empowering melanoma therapy: advances in multifunctional platform research.
Review in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanoma, one of the most aggressive types of skin cancer, has exhibited a continuously rising incidence worldwide, accompanied by a significant mortality risk. Despite ongoing advances in therapeutic approaches, effective and definitive clinical interventions remain limited, severely restricting long-term patient prognosis. In recent years, nanotechnology-based tumor therapies have demonstrated tremendous potential. Among them, iron oxide nanoparticles (IONPs), owing to their excellent biocompatibility, magnetic responsiveness, low cost, and scalability in synthesis, have emerged as a highly promising nanoplatform for melanoma treatment. This review systematically summarizes the physicochemical properties of IONPs and their tumor-targeting mechanisms, with a particular focus on recent advances in their applications for melanoma, including drug-targeted delivery, hyperthermia, Photodynamic therapy (PDT), Chemodynamic therapy (CDT), immunotherapy, and combination therapies. Additionally, the review discusses current challenges and provides perspectives on the future development of IONPs for precision melanoma therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.